Premium
Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir‐resistant cytomegalovirus syndrome ( UL 97 mutation)
Author(s) -
Chong Pearlie P.,
Teiber Dagny,
Prokesch Bonnie C.,
Arasaratnam Reuben J.,
Peltz Matthias,
Drazner Mark H.,
Garg Sonia
Publication year - 2018
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12965
Subject(s) - foscarnet , medicine , ganciclovir , cidofovir , cytomegalovirus , immunology , virology , herpesviridae , human cytomegalovirus , virus , viral disease
Letermovir was approved by the Food and Drug Administration ( FDA ) in November 2017 for use in adult cytomegalovirus ( CMV )‐seropositive allogeneic stem cell transplant ( SCT ) recipients for primary prophylaxis of CMV infection and disease. We report off‐label use of letermovir for secondary prophylaxis of genotype‐confirmed ganciclovir‐resistant cytomegalovirus ( CMV ) syndrome ( UL 97 mutation [C603W]) in a heart transplant recipient initially treated with intravenous cidofovir followed by foscarnet, both discontinued due to unacceptable toxicities.